Diagnosis Value of SEMA4C in Breast Cancer

Tongji Hospital

Status: Not yet enrolling

Conditions: Breast Neoplasm Female

Treatments: Diagnostic Test: Breast cancer group; Diagnostic Test: Benign breast tumor group

Study type: Observational

Funder types: Other

Identifiers

NCT03662633

2018-TJ-BCD

Details and patient eligibility

About

Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C.

Full description

Breast cancer remains the most common cancer in women worldwide, with approximately 1.68 million new cases, and 0.52 million deaths, annually. Meanwhile the incidence of breast cancer continues to increase. Early diagnosis and access to optimum treatment are crucial to reduce mortality associated with breast cancer. Currently, mammography and breast ultrasonography are essential for the detection and diagnosis of disease, and breast magnetic resonance imaging is the choice to estimate the extent of disease and guide appropriate treatment. However, there is no robust biomarkers for early detection of breast cancer.

Semaphorin4C (SEMA4C) has been previously identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs) using in situ laser capture microdissection of lymphatic vessels, followed by cDNA microarray analysis. Moreover, membrane-bound SEMA4C is cleaved by matrix metalloproteinase (MMPs) to release a soluble form of this protein. Therefore, this prospective project aims to assess the early diagnostic value of SEMA4C as a biomarker for breast cancer.

Enrollment: 2,300 estimated patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Receiving no treatment before diagnosis
• Establishing Diagnosis according to biopsy or surgery

Exclusion criteria

• Patients who are not mentally capable of giving written informed consent
• Clinical data missing
• Serum samples doesn't qualified
• Patients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results

Trial design

2,300 participants in 2 patient groups

Breast cancer group

Description:

Patients who have histologically confirmed new diagnosis of breast cancer are recruited.

Treatment:

Diagnostic Test: Breast cancer group

Benign breast tumor group

Description:

Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.

Treatment:

Diagnostic Test: Benign breast tumor group